Related references
Note: Only part of the references are listed.NATALIZUMAB-RELATED PML 2 WEEKS AFTER NEGATIVE ANTI-JCV ANTIBODY ASSAY
Marie-Sarah Gagne Brosseau et al.
NEUROLOGY (2016)
Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment
Stacy Ellen Hatcher et al.
JAMA NEUROLOGY (2016)
EXTENSIVE BRAIN DEMYELINATING LESIONS UNDER NATALIZUMAB: THE ROLE OF ANTI-NATALIZUMAB ANTIBODIES
Rabab Debs et al.
NEUROLOGY (2015)
Tumefactive demyelination and a malignant course in an MS patient during and following fingolimod therapy
M. A. Hellmann et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2014)
Tumefactive MS lesions under fingolimod A case report and literature review
Georg Pilz et al.
NEUROLOGY (2013)
Reduced Diffusion in a Subset of Acute MS Lesions: A Serial Multiparametric MRI Study
P. Eisele et al.
AMERICAN JOURNAL OF NEURORADIOLOGY (2012)
Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy
Tarek A. Yousry et al.
ANNALS OF NEUROLOGY (2012)
Progressive multifocal leukoencephalopathy: a review of the neuroimaging features and differential diagnosis
M. A. Sahraian et al.
EUROPEAN JOURNAL OF NEUROLOGY (2012)
Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal
L. Daelman et al.
MULTIPLE SCLEROSIS JOURNAL (2012)
Share Paper
